Skip to content
Original
mp.weixin.qq.com·· 1 day agoScore68

Alphamab Presents Phase I/II JSKN033 Data in Pretreated Cervical Cancer at 2026 ESMO Proffered Papers, 52.9% ORR at 8.4 mg/kg

In brief

Alphamab Oncology presented Phase I/II data from JSKN033-102 (NCT06770881) in cervical cancer after failure of standard therapy in a rapid oral presentation at ESMO. The 8.4 mg/kg dose group showed an ORR of 52.9%.

Source: mp.weixin.qq.com · mp.weixin.qq.com

#Clinical readout#Oncology#ADCs & conjugates#Bispecifics#Immunotherapy
CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.